UBA1体细胞突变定义复发性多软骨炎中VEXAS亚群
在92例复发性多软骨炎(RP)患者中,7.6%携带UBA1体细胞突变(VEXAS-RP),均为男性、起病年龄≥45岁,常见发热、耳软骨炎、皮肤受累、深静脉血栓和肺部浸润,无气道或肋软骨炎,死亡率高于RP(23% vs 4%,P=0.029)。基于男性、平均红细胞体积>100 fl和血小板<200×10³/μl的决策树算法可100%敏感、96%特异地区分VEXAS-RP与RP。
要点
- RP患者中7.6%存在UBA1突变,均为男性且起病年龄≥45岁。
- VEXAS-RP无气道或肋软骨炎,死亡率高于普通RP(23% vs 4%)。
- 男性、MCV>100 fl、血小板<200×10³/μl可高敏感特异识别VEXAS-RP。
核心结论
- UBA1突变是部分RP患者的致病原因,该亚群以男性、晚发、耳/鼻软骨炎和血液学异常为特征,早期识别重要。
研究设计与样本
- 前瞻性观察队列中92例RP患者接受UBA1外显子组和靶向测序,比较有无UBA1突变者的临床和免疫学特征,并用随机森林法推导临床算法。
主要发现
- 92例RP中7例(7.6%)携带UBA1突变(VEXAS-RP),均为男性,平均起病年龄≥45岁。
- VEXAS-RP常见发热、耳软骨炎、皮肤受累、深静脉血栓和肺部浸润,无气道软骨炎或肋软骨炎。
- VEXAS-RP死亡率23%,RP为4%(P=0.029)。
- VEXAS-RP中急性期反应物升高和血液学异常(如大细胞性贫血、血小板减少、淋巴细胞减少、多发性骨髓瘤、骨髓增生异常综合征)常见。
关键数值与推荐
- 基于男性、平均红细胞体积>100 fl、血小板计数<200×10³/μl的决策树算法区分VEXAS-RP与RP,敏感性100%、特异性96%。
临床怎么用
- 对男性、晚发RP且伴耳/鼻软骨炎和血液学异常者应警惕VEXAS,可依据男性、MCV>100 fl、血小板<200×10³/μl的算法早期识别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Somatic mutations in UBA1 cause a newly defined syndrome known as VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome). More than 50% of patients currently identified as having VEXAS met diagnostic criteria for relapsing polychondritis (RP), but clinical features that characterize VEXAS within a cohort of patients with RP have not been defined. We undertook this study to define the prevalence of somatic mutations in UBA1 in patients with RP and to create an algorithm to identify patients with genetically confirmed VEXAS among those with RP. METHODS: Exome and targeted sequencing of UBA1 was performed in a prospective observational cohort of patients with RP. Clinical and immunologic characteristics of patients with RP were compared based on the presence or absence of UBA1 mutations. The random forest method was used to derive a clinical algorithm to identify patients with UBA1 mutations. RESULTS: Seven of 92 patients with RP (7.6%) had UBA1 mutations (referred to here as VEXAS-RP). Patients with VEXAS-RP were all male, were on average ≥45 years of age at disease onset, and commonly had fever, ear chondritis, skin involvement, deep vein thrombosis, and pulmonary infiltrates. No patient with VEXAS-RP had chondritis of the airways or costochondritis. Mortality was greater in VEXAS-RP than in RP (23% versus 4%; P = 0.029). Elevated acute-phase reactants and hematologic abnormalities (e.g., macrocytic anemia, thrombocytopenia, lymphopenia, multiple myeloma, myelodysplastic syndrome) were prevalent in VEXAS-RP. A decision tree algorithm based on male sex, a mean corpuscular volume >100 fl, and a platelet count <200 ×103 /μl differentiated VEXAS-RP from RP with 100% sensitivity and 96% specificity. CONCLUSION: Mutations in UBA1 were causal for disease in a subset of patients with RP. This subset of patients was defined by disease onset in the fifth decade of life or later, male sex, ear/nose chondritis, and hematologic abnormalities. Early identification is important in VEXAS given the associated high mortality rate.
引用
- Ferrada MA, Sikora KA, Luo Y, et al. Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS. Arthritis Rheumatol. 2021. PMID: 33779074. doi:10.1002/art.41743
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。